Corporate | 3 June 2015 17:22
DGAP-News: STADA Arzneimittel AG / Key word(s): AGM/EGM
2015-06-03 / 17:22
---------------------------------------------------------------------
Bad Vilbel, June 3, 2015 - At the Annual General Meeting of STADA
Arzneimittel AG, which took place today, on June 3, 2015, Chairman of the
Executive Board Hartmut Retzlaff gave a positive summary of financial year
2014 and confirmed the outlook for 2015. "In the past financial year we
were once again faced with significant challenges. However, we were able to
record several successes and to further strengthen our position in a global
market which remains highly competitive", said Retzlaff.
In his remarks, the Chairman of the Executive Board initially discussed the
major developments of financial year 2014, elaborating, among other things,
on the successes achieved in the context of the active acquisition policy
as well as the successful internationalization strategy. In addition, he
talked about the successes that the Group achieved in the area of product
development including its biosimilar activities. Toward the end of his
speech, Retzlaff summarized both the growth-promoting and challenging
framework conditions for the Group and confirmed the outlook for financial
year 2015. With a view to the strategic success factors he showed overall
optimism for continued successful development despite a difficult financial
year 2015. "These success factors, coupled with a highly-motivated and very
capable management team, let us to remain positive in our outlook for the
STADA Group", said Retzlaff in his closing remarks.
The Annual General Meeting endorsed all of the management's proposals.
Accordingly, a dividend unchanged from the previous year of Euro 0.66 per
STADA common share was resolved, with the remaining surplus being carried
forward. In addition, the Executive Board and the Supervisory Board were
confirmed with a high level of approval.
Today's speech script of the Chairman of the Executive Board and the exact
voting results for all items on the agenda can be found at STADA's website
at www.stada.com/agm2015.
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215
/ e-mail: ir@stada.de
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215
/ e-mail: press@stada.de
Or visit us in the Internet at www.stada.com.
---------------------------------------------------------------------
2015-06-03 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Munich, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
365243 2015-06-03